People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy -; proton beam therapy or intensity modulated radiation therapy (IMRT) -; achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Sanofi’s trimmed oncology plans lead to $3B biobucks dent for IGM
Sanofi’s oncology pruning will lead to the evaporation of an estimated $3 billion in potential biobucks for partner IGM Biosciences. The French pharma giant has amended its $6.15